Ranbaxy launches BONISTA- Teriparatide injection for the treatment of osteoporosis in India in collaboration with Virchow Biotech Pvt Ltd, Hyderabad, India.
Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech Pvt Ltd ,
The product has been indigenously researched at Virchow Biotech and developed with aid from the Department of Science and Technology, Government of India.
Commenting on the launch of the product, Mr. Sanjeev I. Dani, Senior Vice President & Regional Director (Asia & CIS), Ranbaxy, said, “With growing longevity, Osteoporosis- a condition characterised by loss of bone mass, would gain increased attention. Ranbaxy has a number of new products in its pipeline including ‘Bonista’, for the Osteoporosis patients who are normally treated by orthopaedics and gynaecologists. Bonista is also a classic example of our endeavours to offer quality biogeneric therapeutic options to doctors and an affordable and efficacious product to patients.”
The Osteoporosis segment in
Osteoporosis is highly prevalent in
Although data on the prevalence of osteoporotic fractures is limited, it is estimated that each year, osteoporosis causes more than 1.5 million fractures, resulting in permanent disability, loss of independence, and death.
Sourced From: Ranbaxy Laboratories Ltd
Ranbaxy Labs stock price
On March 02, 2015, Ranbaxy Laboratories closed at Rs 722.75, up Rs 11.35, or 1.60 percent. The 52-week high of the share was Rs 746.00 and the 52-week low was Rs 335.00.
The latest book value of the company is Rs 25.79 per share. At current value, the price-to-book value of the company was 28.02.
READ MORE ON Ranbaxy Laboratories, BONISTA- Teriparatide injection, Osteoporosis, Virchow Biotech Pvt Ltd, bio-generic , Sanjeev I. Dani
Set email alert for
ADS BY GOOGLE
video of the day
Budget 2015-16: Revive capex through savings on cheap crude says Kotak Sec